CDEK
← All drugs Report issue

sym021

mAbexperimental

Clinical trial activity

4 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Dec 7, 2017 (NCT03311412)

Timeline

2010s

  1. Jan 1, 2017

    Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05162755Phase 1Oct 15, 2021Servier, The START Center for Cancer Care
NCT04672434Phase 1Nov 19, 2020START Midwest, Symphogen A/S
NCT04641871Phase 1Oct 12, 2020START Midwest, Symphogen A/S
NCT03311412Phase 1Dec 7, 2017Symphogen A/S, University of Toronto
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Symphogen A/SFor profit3312017
START MidwestAcademic/Hospital2012020
ServierFor profit1112021
The START Center for Cancer CareAcademic/Hospital1012021
University of TorontoAcademic/Hospital1012017
5 organizations
Page 1 / 1